While targeting CHK1 can be effective in killing cancer cells, there is a risk of affecting normal cells that also rely on CHK1 for managing DNA damage. However, normal cells typically experience lower levels of replication stress compared to cancer cells, which allows for a therapeutic window where cancer cells are more susceptible to CHK1 inhibition than normal cells.
